Arrayit Corporation Ships Clinical Instrumentation and Software to the United States Food and Drug Administration
24 September 2018 - 11:30AM
Sunnyvale, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Arrayit
Corporation (OTC: ARYC), a life sciences and personalized
medicine company, reports the shipment of clinical instrumentation
and quantification software to the United States Food and Drug
Administration (FDA). Arrayit uses the same instrumentation
and software to test for allergy and food intolerance as well as
pipeline indications for ovarian cancer and Parkinson’s Disease
(PD). Testing is performed in the company’s Clinical
Laboratory Improvement Amendments (CLIA) laboratory licensed by the
California Department of Public Health (CDPH) and the Center for
Medicare and Medicaid Services (CMS).
Arrayit recently completed an allergy testing pilot program for
a top retail chain, established a nationwide network of 1,700
allergy sales professionals, met with top officials at the FDA
regarding approval of a major product line, reported the sale of
clinical instrumentation to the FDA, signed allergy testing
contracts with a consortium of 178 medical clinics, received
approval for in-store promotions by a major retailer, announced
allergy testing partnerships with major allergy therapeutics
providers and was approved for direct Medicare billing by CMS.
The clinical instrumentation and software shipped to the FDA,
which regulates consumer products exceeding $1,000,000,000,000 ($1
trillion) in annual revenues, allows hands-on use by FDA
scientists.
Chief Executive Officer Rene Schena states, “Arrayit’s
personalized medicine initiatives are purposefully designed to use
simple, non-invasive finger stick tests. That the FDA chose to
purchase the same clinical microarray instrumentation and software
that Arrayit uses daily enhances the credibility of our approach.
Microarrays are invaluable tools that are transforming healthcare
today.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads
and empowers the research, biotechnology, pharmaceutical, clinical
and healthcare sectors through the discovery, development and
manufacture of proprietary life science and personalized medicine
products and services to advance biomedical research and improve
wellness and human health. Please
visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such
as "expect", "believe", and "should". Although we believe our
expectations are reasonable, our operations involve a number of
risks and uncertainties that are beyond our control, and these
statements may turn out not to be true. Risk factors associated
with our business, including some of the facts set forth herein,
are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
